Ph3 study of HQP1351 in patients with Myeloid Leukemia (POLARIS-2)
Phase III Clinical Trial
A Global Multicenter Open Label Randomized Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)(HQP1351CG301)